Tags : Fibrosis


WuXi Biologics and Aravive Collaborate to Develop Novel High-Affinity Bispecific

Shots: The collaboration leverages WuXi’s WuXiBody platform to develop high-affinity bispecific Ab targeting CCN2 for the treatment of cancer and fibrosis WuXi Biologics will be responsible for biologics discovery, process development, and manufacturing, whereas Aravive will be responsible for pre/ clinical development In 2018, Aravive and WuXi Biologics expanded their manufacturing collaboration for development and […]Read More